Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003350 | 0.86 | ALDH1A1 (0.61) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL15668410 | 0.85 | HTT (0.69) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11248653 | 0.84 | HTT (0.55) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL15765839 | 0.83 | KMT2A (0.68) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11286642 | 0.80 | HTT (0.55) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11416877 | 0.80 | HTT (0.63) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL5383670 | 0.79 | TSHR (0.76) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11412481 | 0.76 | HTT (0.50) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11408725 | 0.76 | TSHR (0.67) | HTTTSHRALDH1A1MAPTKMT2A | |
| SCHEMBL14853296 | 0.75 | TSHR (0.65) | HTTTSHRALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320365-A4 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1320365-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | Bristol-Myers Squibb Company (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6515005-B2 | For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002024200-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | CRH, CRHR1, CRHR2 | HTT 1602/4885TSHR 62/4885ALDH1A1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.